Aclarion Announces Expansion to Santa Monica with Medical Imaging Center of Southern California
BROOMFIELD, Colo., April 02, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ('Aclarion' or the 'Company') (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today its Nociscan product is now available in Santa Monica at Medical Imaging Center of Southern California (MICSC). Until now, MICSC has provided Nociscan exclusively at their Beverly Hills location.
'We are pleased to expand access to Nociscan in our Santa Monica location,' said Bradley Jabour, MD, founder of MICSC. 'MICSC has a proud heritage of adoption of new and novel solutions that add value to our patients and referring physician customers. Nociscan has been an integral part of our Beverly Hills service offering and by adding it in Santa Monica we are expanding our services while replicating the benefits to patients and physicians currently provided in Beverly Hills. Physicians treating low back pain are constantly striving for more and better information when diagnosing and treating patients. Nociscan is helping physicians who treat low back pain and we are pleased to offer Nociscan at both our Los Angeles locations.'
In November 2024, Dr. Jabour was highlighted in an article about Nociscan in the Radiological Society of North America edition of MAGNETOM Flash, a peer-to-peer magazine published by Siemens Healthineers. The article features two physician-user perspectives on Nociscan, one from a spine surgeon and the other from Dr. Jabour's point of view as a radiologist and imaging center owner.
Chronic low back pain (cLBP) is a global healthcare problem with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Los Angeles is the most populous city in California, with an estimated population exceeding 3.8M people, and the second-most populous city in the United States, second only to New York City. Both Los Angeles and New York City are strategically important markets for Aclarion.
Aclarion's Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain.
To find a Nociscan center, view our site map here.
For more information on Nociscan, please email: info@aclarion.com
All organizations cited and/or quotes from individuals not part of Aclarion have reviewed and approved the contents herein.
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy ('MRS'), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as 'anticipates,' 'believes' and 'expects' or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company's current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled 'Risk Factors' in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. SmithPCG Advisory, Inc.ksmith@pcgadvisory.com
Media Contacts:
Jennie KimSPRIG Consultingjennie@sprigconsulting.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
18 hours ago
- Business Upturn
Where the Sea Meets the Skin: Shapellx Unveils Innovative New OceanHug™ Collection Made from Oyster Shells
By GlobeNewswire Published on June 8, 2025, 18:00 IST ORLANDO, Fla., June 08, 2025 (GLOBE NEWSWIRE) — Shapellx , a leading women's shapewear brand, proudly announces the launch of OceanHug™ – a seamless women's wear collection of intimates, outerwear, and shapewear pieces crafted with a first-of-its-kind fabric made from recycled oyster shells. The new sustainable, ocean-inspired collection enhances body contours while delivering the perfect balance of style, comfort, and sustainability. Every year, millions of pounds of oyster shells are discarded, eventually ending up in landfills. Shapellx believes that beauty should never come at the expense of the environment. Every OceanHug™ piece gives new purpose to 33 recycled oyster shells, integrating them into ethically produced, performance-driven fabrics. By turning marine waste into innovation, the collection represents a fresh take on circular fashion by finding a second life for shells that promotes innovation while reducing use of virgin materials. 'As sustainability becomes a top priority for both brands and consumers, Shapellx is proud to lead with innovative materials like oyster protein that combine environmental responsibility with performance-enhancing benefits,' said Shane Shi, Vice President of Shapellx. 'We're committed to delivering more sustainable alternatives without compromising on quality or comfort. OceanHug™ is just the beginning.' The lightweight yet form-fitting OceanHug™ yarn is engineered with breathable, moisture-wicking properties, feeling silky, cool, and comfortable to the touch. The fabric uniquely incorporates collagen peptides and oyster protein fiber, rich in amino acids and trace elements, which can help to nourish the skin and strengthen its barrier. OceanHug™ also offers antibacterial properties, reducing harmful bacteria growth by 2.56%, and is specially processed to be free from irritating chemicals, making it an excellent choice for those with sensitive skin. The new lineup, built with shapewear materials to hug and comfortably embrace the body, comes in soft hues of baby blue, lavender pink, oyster white, and more. The collection includes the following products: OceanHug™ Oyster Reborn Smoothing Bodysuit The delicate lace cup edges expand the coverage around the bust, enhancing the natural bust shape and curve. The waist and abdomen shaping works to tighten and smooth targeted areas for a comfortable, sculpted silhouette. Retails for $54 and is available in sizes S-XXL and colors black, brown, baby blue, oyster white, lavender pink and bright red. OceanHug™ Oyster Reborn T-Shirt Bra The OceanHug ™ Seamless Bra is made with high-elasticity yarn and butter-soft fabric for an ultimate comfort experience. The fixed one-piece cup design reduces the risk of cup-shifting for a supportive fit. The back closure is 7cm wide, compared to the traditional 3.5cm, providing better wraparound coverage and enhanced smoothing. Retails for $49 and is available in sizes S-3XL and colors black, brown, baby blue, oyster white, beige and lavender pink. OceanHug™ Oyster Reborn Smoothing Brief The briefs feature a mid-waist, hip-hugging seamless design for stable coverage, preventing unwanted digging and squeezing while delivering stretch to fit perfectly on all body types. Made from skin-friendly, soft modal fabric, it provides a gentle and refreshing touch on the skin. Retails for $9 and is available in sizes S-3XL and colors black, brown, baby blue, oyster white, beige and lavender pink. OceanHug™ Oyster Reborn Smoothing Cami The V-neckline highlights the collarbone, creating a feminine, flattering look. The built-in 3D molded cups comfortably lift and shape the bust for all-day support. It features an anti-slip grip at the bottom hem to prevent rolling and ensure a smooth, stable fit. The compression fabric around the waist and abdomen smooths the area and provides comfortable shaping. Retails for $49 and is available in sizes S-XXL and colors black, brown, baby blue, oyster white, beige and lavender pink. To celebrate both the OceanHug™ launch and World Ocean Day on June 8, Shapellx hosted a pop-up event in NoHo, New York. Attendees were able to experience the OceanHug™ fabric firsthand and received a special gift. Designed to suit your everyday life and standout moments, Shapellx's new OceanHug™ collection is available to purchase at . To learn more about the collection and keep up with the brand, follow along on Instagram and TikTok . About Shapellx Shapellx is a full-category shapewear brand built on cutting-edge shaping technology and refined design aesthetics. Through premium international retailers such as Nordstrom and its own online platform, Shapellx connects with women who value both quality and style. The brand is dedicated to meeting the dual needs of fashion expression and body contouring in everyday wear, empowering women to radiate confidence from the inside out. Contact:Melina Schaefer [email protected] A video accompanying this announcement is available at Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
21 hours ago
- Yahoo
1 Stock Down 34% This Year to Buy and Hold
Investors are withdrawing their money from stocks like Viking Therapeutics due to the current uncertainty. However, the biotech has a duo of mid-stage candidates that look incredibly promising. Though it carries above-average risk, Viking has significant upside potential. 10 stocks we like better than Viking Therapeutics › Shares of Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech, are down by 34% this year. This poor performance may suggest that recent company-specific developments have rendered the stock less attractive or that it is being affected by broader market issues. The latter is true, at least to some extent, but Viking Therapeutics' thesis has not changed significantly this year. The drugmaker remains attractive compared to most of its similarly sized peers. Here is why. Viking Therapeutics is a clinical-stage biotech. That means the company has no product on the market, generates no revenue, and is consistently unprofitable. Investors aren't too keen on buying shares of companies that fit this profile when broader equities are experiencing significant volatility due to potential macroeconomic issues. In fairness, that makes sense. Clinical-stage biotechs carry above-average risk. Their products may never see the light of day outside the clinic, and even when they do, many do not generate substantial revenue. However, Viking Therapeutics is a bit different. The company is developing medicines across several areas with high unmet needs. First, there is the drugmaker's work in the weight management space. The anti-obesity drug market has experienced significant growth in recent years. Yet, analysts continue to predict that the best is yet to come. Viking Therapeutics' leading candidate in this area, VK2735, is a dual GLP-1/GIP agonist. The only approved medicine of this kind on the market is Eli Lilly's Zepbound, an undisputed leader. Being in the same class as Zepbound doesn't guarantee VK2735's success, but it's still worth pointing out that a similar mechanism of action that led to Zepbound's breakthrough and efficacy could also prove successful for Viking Therapeutics' crown jewel. And more importantly, the investigational medicine has produced better results than almost any other mid-stage candidate in weight management, outside of those being developed by Eli Lilly and Novo Nordisk. That's impressive for a mid-cap biotech, considering significantly larger drugmakers with far more resources are trying to dominate this market. Viking Therapeutics' other mid-stage program, VK2809, performed well in patients with metabolic dysfunction-associated steatohepatitis (MASH), a disease with obesity as one of the main risk factors and whose prevalence is on the rise. However, the U.S. Food and Drug Administration approved just the first MASH medicine last year, although that will likely change soon. The point, though, is that VK2809 could join a relatively young market in a few years and generate massive sales down the road. These two candidates set Viking Therapeutics apart from other clinical-stage biotech companies. It's also worth noting that Viking Therapeutics recently signed a multiyear manufacturing agreement with privately held CordenPharma for VK2735. Per the terms of the deal, CordenPharma will manufacture more than a billion oral formulations of the medicine annually, as well as over 100 million autoinjectors and another 100 million syringes per year. Viking Therapeutics will make payments to CordenPharma, totaling $150 million through 2028. This deal highlights that Viking Therapeutics is already planning some post-commercial activity for its leading candidate. That's a great sign for investors. Viking Therapeutics is developing other candidates, including another weight management product that is still in preclinical studies. Following a similar blueprint, this product is a dual agonist that mimics the action of not just one but two gut hormones: amylin, which helps regulate blood sugar, and calcitonin, which regulates calcium levels. There is slow progress on that front, but Viking Therapeutics' commitment to innovation is impressive for such a small biotech. Now, Viking Therapeutics' most advanced programs could fail in phase 3 studies. If that happens, especially with VK2735, the stock price is likely to plummet. That's a significant risk to consider. That's why the stock is probably not suitable for risk-averse investors. However, those who are comfortable with volatility should strongly consider initiating a small position in the stock. If the business goes under, which isn't that rare for smaller biotech companies, your losses will be relatively small so long as the company makes a tiny portion of your overall portfolio. But there is significant upside potential that those who invest in Viking Therapeutics today could enjoy over the long run. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Prosper Junior Bakiny has positions in Eli Lilly, Novo Nordisk, and Viking Therapeutics. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy. 1 Stock Down 34% This Year to Buy and Hold was originally published by The Motley Fool
Yahoo
a day ago
- Yahoo
1 Stock Down 34% This Year to Buy and Hold
Investors are withdrawing their money from stocks like Viking Therapeutics due to the current uncertainty. However, the biotech has a duo of mid-stage candidates that look incredibly promising. Though it carries above-average risk, Viking has significant upside potential. 10 stocks we like better than Viking Therapeutics › Shares of Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech, are down by 34% this year. This poor performance may suggest that recent company-specific developments have rendered the stock less attractive or that it is being affected by broader market issues. The latter is true, at least to some extent, but Viking Therapeutics' thesis has not changed significantly this year. The drugmaker remains attractive compared to most of its similarly sized peers. Here is why. Viking Therapeutics is a clinical-stage biotech. That means the company has no product on the market, generates no revenue, and is consistently unprofitable. Investors aren't too keen on buying shares of companies that fit this profile when broader equities are experiencing significant volatility due to potential macroeconomic issues. In fairness, that makes sense. Clinical-stage biotechs carry above-average risk. Their products may never see the light of day outside the clinic, and even when they do, many do not generate substantial revenue. However, Viking Therapeutics is a bit different. The company is developing medicines across several areas with high unmet needs. First, there is the drugmaker's work in the weight management space. The anti-obesity drug market has experienced significant growth in recent years. Yet, analysts continue to predict that the best is yet to come. Viking Therapeutics' leading candidate in this area, VK2735, is a dual GLP-1/GIP agonist. The only approved medicine of this kind on the market is Eli Lilly's Zepbound, an undisputed leader. Being in the same class as Zepbound doesn't guarantee VK2735's success, but it's still worth pointing out that a similar mechanism of action that led to Zepbound's breakthrough and efficacy could also prove successful for Viking Therapeutics' crown jewel. And more importantly, the investigational medicine has produced better results than almost any other mid-stage candidate in weight management, outside of those being developed by Eli Lilly and Novo Nordisk. That's impressive for a mid-cap biotech, considering significantly larger drugmakers with far more resources are trying to dominate this market. Viking Therapeutics' other mid-stage program, VK2809, performed well in patients with metabolic dysfunction-associated steatohepatitis (MASH), a disease with obesity as one of the main risk factors and whose prevalence is on the rise. However, the U.S. Food and Drug Administration approved just the first MASH medicine last year, although that will likely change soon. The point, though, is that VK2809 could join a relatively young market in a few years and generate massive sales down the road. These two candidates set Viking Therapeutics apart from other clinical-stage biotech companies. It's also worth noting that Viking Therapeutics recently signed a multiyear manufacturing agreement with privately held CordenPharma for VK2735. Per the terms of the deal, CordenPharma will manufacture more than a billion oral formulations of the medicine annually, as well as over 100 million autoinjectors and another 100 million syringes per year. Viking Therapeutics will make payments to CordenPharma, totaling $150 million through 2028. This deal highlights that Viking Therapeutics is already planning some post-commercial activity for its leading candidate. That's a great sign for investors. Viking Therapeutics is developing other candidates, including another weight management product that is still in preclinical studies. Following a similar blueprint, this product is a dual agonist that mimics the action of not just one but two gut hormones: amylin, which helps regulate blood sugar, and calcitonin, which regulates calcium levels. There is slow progress on that front, but Viking Therapeutics' commitment to innovation is impressive for such a small biotech. Now, Viking Therapeutics' most advanced programs could fail in phase 3 studies. If that happens, especially with VK2735, the stock price is likely to plummet. That's a significant risk to consider. That's why the stock is probably not suitable for risk-averse investors. However, those who are comfortable with volatility should strongly consider initiating a small position in the stock. If the business goes under, which isn't that rare for smaller biotech companies, your losses will be relatively small so long as the company makes a tiny portion of your overall portfolio. But there is significant upside potential that those who invest in Viking Therapeutics today could enjoy over the long run. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Prosper Junior Bakiny has positions in Eli Lilly, Novo Nordisk, and Viking Therapeutics. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy. 1 Stock Down 34% This Year to Buy and Hold was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
